Thermo Fisher Scientific Collaborates to Introduce Fully Automated Cell Line Automation Platform
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics
Posts by
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics
Thermo Fisher’s latest net-zero milestone to be achieved through 200-megawatt solar project
RAVENSBURG, Germany & RANKWEIL, Austria & SKOKIE, Ill.--(BUSINESS WIRE)--With the increasing drug development for novel therapeutics, a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to help meet the demand for complex fill and finish solutions. And, while the stages of early drug development are challenging, Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge by offering comprehensive expert manufacturing services for clinical trials and supporting their customer products path to commercialization. A testament to this commitment is evidenced by the success of its Skokie facility which has already contributed to bring five new customer products to market since it began full operations in 2011, with another four expected to launch in the next months.
Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients
Expansion of manufacturing facility in North Carolina will increase the number of patients who may benefit from the company's medicines
Charles River Edinburgh has been awarded Top Employer UK status for 2023. This internationally recognised award is given to organisations that show a passion and commitment to enriching the world of work for their employees. This is the second consecutive year that CRL EDI has received this award!
Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services
BOSTON, MA and UNIONDALE, NY, January 17, 2023 – Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp (NASDAQ:ANGN) under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. The combined company will continue under the Elicio Therapeutics name and will focus on advancing Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago’s outstanding shares on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.